Pharmacyclics Reaches New 52-Week High (PCYC)

NEW YORK ( TheStreet) -- Pharmacyclics Incorporated (Nasdaq: PCYC) hit a new 52-week high Wednesday as it is currently trading at $27.73, above its previous 52-week high of $27.69 with 540,074 shares traded as of 2:40 p.m. ET. Average volume has been 823,600 shares over the past 30 days.

Pharmacyclics has a market cap of $1.25 billion and is part of the health care sector and drugs industry. Shares are up 76.9% year to date as of the close of trading on Tuesday.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 110.5, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pharmacyclics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Pharmacyclics Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015